About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 108 record(s)
Req # A-2021-001959
Respecting ATIA requests A-2021-000734, A-2021-001017, and A-2021-001140, please provide the following records: Health Product and Food Branch (HPFB) recommendations, and summary documents thereof, completed Extension Justification Form(s), records referenced by any of the documents above.Organization: Health Canada
September 2022
Req # A-2022-000243
Health Canada issued a public advisory (Identification #RA-64122) on April 28, 2022 advising that Apotex Inc. is recalling five lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of N-nitrosodimethylamine (NDMA) above the acceptable level. Copies of any documentation or other information identifying the quantity of pills affected by the recall as well as the levels and/or concentrations of NDMA detected through testing of the recalled Apo-Acyclovir tablets. Any information in Health Canada’s possession concerning distribution of Apo-Acyclovir lots contaminated with NDMA by Apotex outside of Canada.Organization: Health Canada
September 2022
Req # A-2022-000257
The number of rapid tests distributed to government employees by department for each month and for each product type since September 2020. The number of rapid tests distributed to the private sector by organization during the same timeframe.Organization: Health Canada
September 2022
Req # A-2022-000371
The Health Canada approval letter for Vertex Pharmaceutical's trial to be carried out in Canada: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (ClinicalTrials.gov Identifier: NCT04786262).Organization: Health Canada
September 2022
Req # A-2022-000391
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient buprenorphine. Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for buprenorphine which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22.Organization: Health Canada
September 2022
Req # A-2022-000392
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient desmopressin. Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for desmopressin which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22.Organization: Health Canada
September 2022
Req # A-2022-000394
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient thiotepa. Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for thiotepa which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22.Organization: Health Canada
September 2022
Req # A-2022-000421
All receipts for the expense referred to in Sessional Paper 8555-441-494, tabled in the House of Commons on June 8, 2022, with the following vendor, amount, date of expenditure, and file number: Gilles Blais Distribution, $77.32, March 17th, 2022, 1162316.Organization: Health Canada
September 2022
Req # A-2022-000428
All receipts for the expense referred to in Sessional Paper 8555-441-494, tabled in the House of Commons on June 8, 2022, with the following vendor, amount, date of expenditure, and file number: Food Fare QPS WI, $142.40 March 25th, 2022, 241926Organization: Health Canada
September 2022
Req # A-2022-000464
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredients lidocaine-prilocaine.Organization: Health Canada
September 2022